Literature DB >> 16389945

Proteases and glioma angiogenesis.

Sajani S Lakka1, Christopher S Gondi, Jasti S Rao.   

Abstract

Angiogenesis, the process by which new branches sprout from existing vessels, requires the degradation of the vascular basement membrane and remodeling of the ECM in order to allow endothelial cells to migrate and invade into the surrounding tissues. Serine, metallo, and cysteine proteinases are 3 types of a family of enzymes that proteolytically degrade various components of extracellular matrix. These proteases release various growth factors and also increase adhesive molecules and signaling pathway molecules upon their activation, which plays a significant role in angiogenesis. Downregulation of these molecules by antisense/siRNA or synthetic inhibitors decreases the levels of these molecules, inhibits the release of growth factors, and decreases the levels of various signaling pathway molecules, thereby leading to the inhibition of angiogenesis. Furthermore, MMPs degrade specific substrates and release angiogenic inhibitors which inhibit angiogenesis. Downregulation of 2 molecules, such as uPA and uPAR, uPAR and MMP-9, or Cathepsin B and MMP-9, are more effective to inhibit angiogenesis rather than downregulation of single molecules. However, careful testing of these combinations are most important because multiple effects of these combinations play a significant role in angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16389945     DOI: 10.1111/j.1750-3639.2005.tb00118.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  55 in total

1.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

Review 2.  Biology of angiogenesis and invasion in glioma.

Authors:  Matthew C Tate; Manish K Aghi
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  Proteolysis of the matricellular protein hevin by matrix metalloproteinase-3 produces a SPARC-like fragment (SLF) associated with neovasculature in a murine glioma model.

Authors:  Matt Weaver; Gail Workman; Chad R Schultz; Nancy Lemke; Sandra A Rempel; E Helene Sage
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

4.  Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.

Authors:  Wan-Nan Chen; Jin-Yan Chen; Bo-Yan Jiao; Wan-Song Lin; Yun-Li Wu; Ling-Ling Liu; Xu Lin
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

5.  Expression of β-adrenergic receptors in pediatric malignant brain tumors.

Authors:  Iacopo Sardi; Laura Giunti; Cecilia Bresci; Anna Maria Buccoliero; Duccio Degl'innocenti; Stefania Cardellicchio; Gianna Baroni; Francesca Castiglione; Martina DA Ros; Patrizio Fiorini; Sabrina Giglio; Lorenzo Genitori; Maurizio Aricò; Luca Filippi
Journal:  Oncol Lett       Date:  2012-10-23       Impact factor: 2.967

6.  MMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice.

Authors:  Krishna Kumar Veeravalli; Chandramu Chetty; Shivani Ponnala; Christopher S Gondi; Sajani S Lakka; Daniel Fassett; Jeffrey D Klopfenstein; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  PLoS One       Date:  2010-07-15       Impact factor: 3.240

7.  Comparative expression pattern of Matrix-Metalloproteinases in human glioblastoma cell-lines and primary cultures.

Authors:  Carsten Hagemann; Jelena Anacker; Stefanie Haas; Daniela Riesner; Beate Schömig; Ralf-Ingo Ernestus; Giles H Vince
Journal:  BMC Res Notes       Date:  2010-11-10

8.  Progress on antiangiogenic therapy for patients with malignant glioma.

Authors:  Manmeet S Ahluwalia; Candece L Gladson
Journal:  J Oncol       Date:  2010-04-06       Impact factor: 4.375

Review 9.  Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Authors:  David A Reardon; Patrick Y Wen; Annick Desjardins; Tracy T Batchelor; James J Vredenburgh
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

Review 10.  Galectins and gliomas.

Authors:  Marie Le Mercier; Shannon Fortin; Véronique Mathieu; Robert Kiss; Florence Lefranc
Journal:  Brain Pathol       Date:  2009-04-07       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.